Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jerome Benedict Durso
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Beta
- 0.18
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.04
Financials
Revenue
$0.00-100.0%Net Income
$-31.61M-140.6%EBITDA
$-30.49MFree Cash Flow
$-37.81M-145.6%EPS (diluted)
$-0.15-100.0%Shares Outstanding (diluted)
205.27M+89491.7%Operating Expenses
$35.70MCash & Debt
$265.06MReturn of Capital
$0.00Revenue by Segment (annual)
$3.70MDividend per Share
$873.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $41.0K | $-88.09M | $-1.00 |
| 2024 | $20.0K | $-95.06M | $-1.34 |
| 2023 | $426.0K | $-88.45M | $-1.66 |
| 2022 | $-68.0K | $-84.71M | $-1.81 |
| 2021 | $4.41M | $-97.09M | $-2.35 |
| 2020 | $8.19M | $-49.04M | $-1.91 |
| 2019 | $5.80M | $-20.52M | $-1.56 |
| 2018 | $10.33M | $-39.17M | $-13.98 |
| 2017 | $41.5K | $-46.43M | $-108.77 |
| 2016 | $5.23M | $193.85M | $-49.80 |
| 2015 | $10.64M | $-3.44M | $-16.13 |
| 2014 | $10.19M | $-9.96M | $-51.91 |
| 2013 | $17.91M | $-11.72M | $-69.40 |
| 2012 | $25.18M | $-4.92M | $-30.55 |
Valuation
ALThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (19)
- Newsglobenewswire.com·3d ago·Neutral
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m.
View source ↗ - Newszacks.com·9d ago·Negative
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.
View source ↗ - Newsmarketbeat.com·10d ago·Negative
What Altimmune (ALT) Said on Its Q3 Earnings Call Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration on a potential phase III program in alcohol use disorder.
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Altimmune Announces Third Quarter 2026 Financial Results and Business Update Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, N.J.
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
… new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denv…
View source ↗ - Newsprnewswire.com·39d ago·Neutral
Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets MCLEAN, Va., Oct. 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, today announced that Altair Semiconductor, a world leader in cellular IoT chips, is integrating Iridium NTN Direct℠ capability into Altair's ALT1350 and next-generation ALT1550 IoT chi…
View source ↗ - Newsmarketbeat.com·52d ago·Positive
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
Altimmune to Participate in Stifel Cardiometabolic Forum GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
View source ↗ - Newszacks.com·72d ago·Neutral
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Alpha AI Corporation ("Alpha AI"), developer of the Alpha Liquid Terminal ("ALTx"), today announced the relaunch of its platform as the ALT/X Compute Terminal , refocusing the product on pricing, power and capacity data for the global AI compute market.
View source ↗ - Newszacks.com·95d ago·Negative
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
View source ↗ - Newszacks.com·95d ago·Positive
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
View source ↗ - Newszacks.com·101d ago·Negative
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Altimmune Q2 Earnings Call Highlights Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Altimmune Announces Second Quarter 2026 Financial Results and Business Update Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.18 per share
Typical surprise +15.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.15 vs $-0.13miss
- Tue, Aug 11$-0.12 vs $-0.14beat
- Wed, May 13$-0.18 vs $-0.25beat
- Thu, Mar 5$-0.27 vs $-0.25miss
- Thu, Nov 6$-0.21 vs $-0.29beat
- Tue, Aug 12$-0.27 vs $-0.32beat
Estimates and results for ALT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALT officers and directors.
- Bought
- $466k
- Sold
- —
15 trades
0 trades
- Menziuso Richard Thomasbought
- Weaver Gregory Lbought
- Pisano Waynebought
- Durso Jerome Benedictbought
- Durso Jerome Benedictbought
- Gill Johnbought
- Weaver Gregory Lbought
- Durso Jerome Benedictbought
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
